Voquezna® (vonoprazan) – New indication
July 18, 2024 - Phathom Pharmaceuticals announced the FDA approval of Voquezna (vonoprazan), for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults.
July 18, 2024 - Phathom Pharmaceuticals announced the FDA approval of Voquezna (vonoprazan), for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults.